Tumor Suppressor Par-4

Role in Cancer and Other Diseases

Buch | Hardcover

X, 331 Seiten

2021 | 1st ed. 2021
Springer International Publishing (Verlag)
978-3-030-80557-9 (ISBN)

Artikel merken

Par-4 is a naturally occurring tumor suppressor. Studies have indicated that overexpression of Par-4 selectively induces apoptosis in cancer cells while leaving normal, health, cells unaffected. Mechanisms contributing to this cancer-selective action of Par-4 have been associated with PKA activation of intracellular Par-4 in cancer cells or GRP78 expression primarily on the surface of cancer cells. On the other hand, endogenous Par-4 sensitizes cells to the action of a broad range of apoptotic inducers acting via the extrinsic and intrinsic pathways. A number of binding partners of Par-4 have been identified and shown to regulate Par-4 function in cancer and other diseases, such as Alzheimer's and major depression. Recent studies have recognized a number of natural products, dietary supplements, synthetic molecules and FDA-approved drugs that induce the secretion of Par-4 protein to cause apoptosis in primary or metastatic tumors, one of which is in clinical trials. More than 50 different laboratories worldwide are involved in Par-4 based research of this unique protein that has progressed from the bench to clinical trials.

This second, companion volume will provide a comprehensive overview of Par-4's role in cancer and other diseases. Chapters are written by leading researchers, and will be useful for a broad audience across the scientific community, particularly students and trainees, who are the next generation of scientists and clinicians to participate in new studies and discoveries on Par-4.

lt;b> Vivek M. Rangnekar, Ph.D. is Professor and Alfred Cohen Chair in Oncology Research in the Department of Radiation Medicine and Associate Director of the Markey Cancer Center at the University of Kentucky. His laboratory studies the molecular cross-talk between oncogenes and tumor suppressor genes in an effort to tilt the balance in favor of tumor suppressor function. Dr. Rangnekar originally identified and discovered the tumor suppressor protein Par-4/PAWR in 1993.

Introduction
Part 1Chapter 1. Role of Par-4 in lung cancerChapter 2. Prostate apoptosis response-4 in nasopharyngeal carcinomaChapter 3. Role of Par-4 in Chemoresistance and targeted therapies in ovarian and endometrial cancersChapter 4. Regulation of Par-4 and role in GI tumorsChapter 5. Role of Par-4 in prostate cancerChapter 6. Activation of apoptosis by Par-4 in pancreatic cancerChapter 7. Role of Par-4 and GRP78 in GlioblastomaChapter 8. Role of Par-4 in breast cancer recurrenceChapter 9. Involvement of Par-4 in breast cancerChapter 10. Role of endogenous Par-4 in CLLChapter 11. Role of Par-4 in inhibition of TCL1 induced growthChapter 12. Par-4/THAP in survival of T-cell acute lympoblastic leukemia cellsChapter 13. Par-4 expression in cholangiocarcinomaChapter 14. Par-4 suppresses breast cancer growth and invasion of breast cancer cellsChapter 15. PAWR as direct SRC-1/HOXC11 suppression targetChapter 16. Par-4 cleavage is required for TNF induced apoptosisChapter 17. Par-4 secretagoguesChapter 18. Recombinant production and characterization of SACChapter 19. Anti-tumor effects of plant derived Par-4Chapter 20. Par-4 in Mycobacterium tuberculosis Infected Macrophages
Part 2 - Role in other DiseasesChapter 21. Role of Par-4 in ceramide inducible effects in neuronsChapter 22. Role of Par-4 in Alzheimers diseaseChapter 23. Dopamine signaling in association with induction of Par-4 protein expressionChapter 24. Par-4 (PAWR) in major depressive disorderChapter 25. Par-4 dependent apoptosis of islet beta cells in type 2 diabetesChapter 26. Par-4 in cardiac fibroblast senescenceChapter 27. Par-4 in ocular development and diseaseChapter 28. Par-4 in apoptosis during human salivary gland developmentChapter 29. Suppression of Par-4 protects human renal proximal tubule cells from apoptosisChapter 30. Lessons from knockout mice
Part 3 - From Bench to BedsideChapter 31. Par-4 secretagogues in clinical trialsChapter 32. Potential of Par-4 as a therapeutic target for cancer

Erscheinungsdatum	22.12.2021
Zusatzinfo	X, 331 p. 121 illus., 93 illus. in color.
Verlagsort	Cham
Sprache	englisch
Maße	210 x 279 mm
Gewicht	1077 g
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
Themenwelt	Medizin / Pharmazie ► Studium
Schlagworte	Breast Cancer • cardiac fibroblast senescence • CLL • dopamine signaling • Endometrial Cancer • GI tumors • glioblastoma • Lung Cancer • Major depression • nasopharyngeal carcinoma • ocular development • ovarian cancer • Pancreatic cancer • Prostate Cancer • Protein Expression • SAC • TCL1 • THAP • TNF • type 2 diabetes
ISBN-10	3-030-80557-3 / 3030805573
ISBN-13	978-3-030-80557-9 / 9783030805579
Zustand	Neuware